Pancreatic cancer 4

Common Name(s)

Pancreatic cancer 4

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 4" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 4" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

http://www.pancan.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Pancreatic cancer 4" returned 47 free, full-text research articles on human participants. First 3 results:

Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial.
 

Author(s): Aurélien Lambert, Marta Jarlier, Sophie Gourgou Bourgade, Thierry Conroy

Journal:

 

Hohla et al. suggested that female gender could positively predict response to FOLFIRINOX in patients with advanced pancreatic cancer. In this study, we explored the response to the FOLFIRINOX regimen by gender within the trial PRODIGE4/ACCORD 11.

Last Updated: 31 Dec 1969

Go To URL
Linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells.
 

Author(s): Yuran Gao, Zhicheng Zhang, Kai Li, Liying Gong, Qingzhu Yang, Xuemei Huang, Chengcheng Hong, Mingfeng Ding, Huanjie Yang

Journal:

 

The acquisition of epithelial-mesenchymal transition (EMT) and/or existence of a sub-population of cancer stem-like cells (CSC) are associated with malignant behavior and chemoresistance. To identify which factor could promote EMT and CSC formation and uncover the mechanistic role ...

Last Updated: 31 Dec 1969

Go To URL
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
 

Author(s): John P Neoptolemos, Daniel H Palmer, Paula Ghaneh, Eftychia E Psarelli, Juan W Valle, Christopher M Halloran, Olusola Faluyi, Derek A O'Reilly, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Alan Anthoney, Pehr Lind, Bengt Glimelius, Stephen Falk, Jakob R Izbicki, Gary William Middleton, Sebastian Cummins, Paul J Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Yuk Ting Ma, Kinnari Patel, David Sherriff, Rubin Soomal, David Borg, Sharmila Sothi, Pascal Hammel, Thilo Hackert, Richard Jackson, Markus W Büchler,

Journal: Lancet. 2017 03;389(10073):1011-1024.

 

The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Pancreatic cancer 4" returned 6 free, full-text review articles on human participants. First 3 results:

Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factor? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
 

Author(s): Soonmo Peter Kang, Muhammad Wasif Saif

Journal:

 

Diabetes mellitus and its related factors such as hyperinsulinemia have been linked to various cancer risks and outcomes. Previous research has offered inconsistent results in terms of relationship between diabetes and pancreatic cancers. Establishing clear association between these ...

Last Updated: 31 Dec 1969

Go To URL
Pancreatic cancer and thrombosis. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
 

Author(s): Manasi M Shah, Mumhammad Wasif Saif

Journal:

 

Although pancreatic cancer is recognized as a major risk factor for venous thromboembolism, the exact magnitude of the problem is not known. The incidence varies from 17% to 57% depending on different studies. The effect of venous thromboembolism on outcomes in not well defined and ...

Last Updated: 31 Dec 1969

Go To URL
Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
 

Author(s): Bryan W Chang, Eduardo Siccion, Muhammad Wasif Saif

Journal:

 

Pancreatic cancer is the 4th leading cancer cause mortality in both men and women. Pancreatic cancer is usually diagnosed in the advanced setting, and only 10-15% of patients present with operable disease. About 25% are locally advanced and unresectable and the rest are metastatic. ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Last Updated: 2 May 2018

Go to URL
Dynamic Changes of Sera Immunoglobulin G4 and Interleukin-10 in the Patients of Pancreatic Cancer After Chemotherapy
 

Status: Recruiting

Condition Summary: Pancreatic Neoplasms; Inflammation

 

Last Updated: 24 Jan 2016

Go to URL

Last Updated: 9 Mar 2018

Go to URL